Immunobiology. 2023 Jan;228(1):152311.
Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation
GSK1120212 (Trametinib) purchased from AbMole
Cancer Res Commun. 2022 Aug.
Pharmacological inhibition of SHP2 blocks both PI3K and MEK signaling in low-epiregulin HNSCC via GAB1
GSK1120212 (Trametinib) purchased from AbMole
Oncogene. 2020 Apr;39(15):3163-3178.
The EGFR-ZNF263 Signaling Axis Silences SIX3 in Glioblastoma Epigenetically
GSK1120212 (Trametinib) purchased from AbMole
Cancer Cell. 2018 Aug 16;pii: S1535-6108(18)30318-0.
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.
GSK1120212 (Trametinib) purchased from AbMole
Int J Mol Sci 2018 Jan 18;19(1) pii: E289.
BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
GSK1120212 (Trametinib) purchased from AbMole
Biochem Pharmacol. 2015 Aug 15;323-36.
Arctigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells via an mTORC1-dependent pathway.
GSK1120212 (Trametinib) purchased from AbMole
J Biol Chem. 2014 Sep 26;289(39):27090-104.
Shock wave treatment enhances cell proliferation and improves wound healing by ATP release-coupled extracellular signal-regulated kinase (ERK) activation.
GSK1120212 (Trametinib) purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | DO4, MM415, MM485, SK-MEL-2, MaMel30I and MaMel27II |
Preparation method | cells were plated in 96-well plates with a density of 4000-8000 cells per well and incubated for 24 h at 37 °C with 5% C02. Then cells were incubated with increasing drug concentrations and their combinations. Cell viability was measured with the CellTiter-Glo (CTG) Luminescent Cell Viability Assay (Promega; Madison, Wisconsin, USA) according to the manufacturer’s protocol. Luminescence was measured on the SynergyHT plate reader (BioTek, Vermont, USA) using Gen5 software (Version 1.11.5). For apoptotic assays, cells were plated in 12-well plates and treated with DMSO, trametinib, metformin or combinations. After 72hrs apoptosis was assessed using the Dead Cell Apoptosis Kit with Annexin V Alexa Fluor 488 & Propidium Iodide according to the manufacturer’s protocol (Invitrogen; V13241) with the AccuriC6 Flow Cytometer using the CFlow software (Version 1.0.227.4). |
Concentrations | 0.2-30nM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | Tumor induction on the skin of the Tyr::CreERT2; PtenLoxP/LoxP;BrafCA/+ mice |
Formulation | dissolved in 0.5% hydroxypropyl methylcellulose (Sigma-Aldrich) and 0.2% Tween-80 (Sigma-Aldrich) |
Dosages | 0.75 mg/kg, once daily |
Administration | orally |
Molecular Weight | 615.39 |
Formula | C26H23FIN5O4 |
CAS Number | 871700-17-3 |
Solubility (25°C) | DMSO 30 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related MEK Products |
---|
MAP855
MAP855 is a potent, selective and orally effective ATP-competitive MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 inhibits wild-type and mutant MEK1/2 equally. |
WAY-114228
WAY-114228 is a MEK1 inhibitor. |
Trametinib (DMSO solvate)
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. |
Selumetinib sulfate
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. |
MEK inhibitor
MEK inhibitor is a potent MEK inhibitor with antitumor potency. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.